Summary
Thirty-one patients with multiple myeloma refractory to therapy or relapsing after response to initial therapy were treated with Fludarabine Phosphate utilizing a daily intravenous schedule for five consecutive days. There were no objective responses seen and only one patient showed clinical improvement. Myelosuppression manifest as leucopenia and granulocytopenia was the primary toxicity seen. Fludarabine Phosphate is inactive in previously treated myeloma patients when given by the daily intravenous route.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dow LW, Bell DE, Poulakos L, Freidland A: Differences in metabolism and cytotoxicity between 9-β-D-Arabinofuranosyladenine and 9-β-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts. Cancer Res 40: 1405–1410, 1980
Brockman RW, Cheng YC, Schabel FM Jr, Montgomery JA: Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine L 1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40: 3610–3615, 1980
Leiby JM, Snider KM, Kraut EH, Metz EN, Malspeis L, Grever MR: Phase II trial of 9-β-D-arabinofuranosyl-2-fIuoroadenine 5-monophosphate in non-Hodgkin's lymphoma. Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47: 2711–2719, 1987
Grever MR, Coltman CA, Files JC, Greenberg BR, Hutton JJ, Talley RL, Von Hoff DD, Balcerzak SP: Fludarabine monophosphate in chronic lymphocytic leukemia. Blood 68, Vol. 5, Suppl #1, 223a, 1986
Durie BM, Salmon SE: A clinical staging system for multiple myeloma. Cancer Res 36: 842–854, 1975
Hurst PG, Habib M, Garewal H, Bluestein M, Paquin M, Greenberg BR: Pulmonary toxicity associated with fludarabine monophosphate. Invest New Drugs 5: 207–210, 1987
Grever MR, Leiby JM, Kraut EH, Neidhart JA, Malspeis L, Balcerzak SP: A Phase I investigation of 2-Fluoro-Ara-AMP in refractory leukemia. Blood 64 (Suppl #1): 165a, 1984
Author information
Authors and Affiliations
Additional information
Address for offprints: Southwest Oncology Group (SWOG-8409), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, Texas 78229-6197, USA
Rights and permissions
About this article
Cite this article
Kraut, E.H., Crowley, J.J., Grever, M.R. et al. Phase II study of Fludarabine Phosphate in multiple myeloma. Invest New Drugs 8, 199–200 (1990). https://doi.org/10.1007/BF00177259
Issue Date:
DOI: https://doi.org/10.1007/BF00177259